
VEXAS syndrome is a newly described adult-onset autoinflammatory disorder, predominantly affecting males (median age, 68), and recognized by somatic mutations in the UBA1 gene in blood-forming cells of the X chromosome. This rare disease causes systemic inflammation and abnormalities in the blood, with high morbidity and mortality when untreated.
VEXAS syndrome has been defined by mutations in the UBA1 gene and represents a rare but life-threatening condition affecting mainly men over the age of 50. Thus, early diagnosis of VEXAS is critical, since there is no prevention, and it probably has an overlap with other inflammatory conditions concerning signs and symptoms. Making the diagnosis early on may ease symptoms and ultimately prolong survival with timely diagnosis, appropriate treatment with steroids or immunosuppressants, or definitive therapy with a continued option of allogeneic bone marrow transplant. This is the most exciting area of research with new therapies, so education about this condition and timely interventions for at-risk patients is paramount.
Disclaimer- This information is for educational purposes only and is not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment of any medical condition.
Musk's X, major labels end dispute over music on social-media platform
By Blake Brittain July 17 (Reuters) - A group of major music publishers including Universal…
Shein secures nod from Hong Kong listing committee for IPO, sources say
HONG KONG, July 17 (Reuters) - Shein has won approval from the Hong Kong stock…
Private credit roundup – Discounts show the cost of getting out
By Patturaja Murugaboopathy July 17 (Reuters) - Pressure in private markets is showing up in…